GSTO1 overexpression has been reported in CRC patients [102], and in vitro studies relate this condition to cancer progression and development of drug resistance, particularly to platinum-containing compounds, by activation of survival pathways (AKT and ERK1/2) and inhibition of apoptotic mediators (JNK1) [95]. The gene discussed is GSTO1; the disease is colorectal carcinoma.